170 related articles for article (PubMed ID: 35870182)
1. Arylsulfatase I is a prognostic biomarker for head and neck squamous cell carcinoma and Pan-cancer.
Shen Y; Wei Z; Zhou C; Song J; Wang J; Wang J; Wu L; Fang S; Shen Z
J Clin Lab Anal; 2022 Sep; 36(9):e24600. PubMed ID: 35870182
[TBL] [Abstract][Full Text] [Related]
2. Constructing a prognostic model for head and neck squamous cell carcinoma based on glucose metabolism related genes.
Liu Y; Liu N; Zhou X; Zhao L; Wei W; Hu J; Luo Z
Front Endocrinol (Lausanne); 2023; 14():1245629. PubMed ID: 37876534
[TBL] [Abstract][Full Text] [Related]
3. Integrated analysis of diagnostic, prognostic value and potential drug treatment of GSDME in head and neck squamous cell carcinoma.
Hu R; Lu M; She L
Eur Arch Otorhinolaryngol; 2023 Sep; 280(9):4239-4253. PubMed ID: 37204444
[TBL] [Abstract][Full Text] [Related]
4. Identification of the MMP family as therapeutic targets and prognostic biomarkers in the microenvironment of head and neck squamous cell carcinoma.
Liu M; Huang L; Liu Y; Yang S; Rao Y; Chen X; Nie M; Liu X
J Transl Med; 2023 Mar; 21(1):208. PubMed ID: 36941602
[TBL] [Abstract][Full Text] [Related]
5. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
Sun K; Chen RX; Li JZ; Luo ZX
Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
[TBL] [Abstract][Full Text] [Related]
6. FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.
Liang H; Zhang C; Li C; Li C; Wang Y; Lin H
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34028536
[TBL] [Abstract][Full Text] [Related]
7. TPPP3 Associated with Prognosis and Immune Infiltrates in Head and Neck Squamous Carcinoma.
Yang Z; Li X; Li J; Su Q; Qiu Y; Zhang Z; Zhang L; Mo W
Biomed Res Int; 2020; 2020():3962146. PubMed ID: 33083464
[TBL] [Abstract][Full Text] [Related]
8. FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis.
Huang J; Liang B; Wang T
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34269372
[TBL] [Abstract][Full Text] [Related]
9. Interferon Regulatory Factor Family Genes: At the Crossroads between Immunity and Head and Neck Squamous Carcinoma.
Liu S; Wang Z
Dis Markers; 2022; 2022():2561673. PubMed ID: 35664436
[TBL] [Abstract][Full Text] [Related]
10. Identification of the Potential Correlation between Tumor Protein 73 and Head and Neck Squamous Cell Carcinoma.
Chen Y
Dis Markers; 2022; 2022():6410113. PubMed ID: 35756491
[TBL] [Abstract][Full Text] [Related]
11. Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma.
Chai F; Zhang J; Fu T; Jiang P; Huang Y; Wang L; Yan S; Yan X; Yu L; Xu Z; Wang R; Xu B; Du X; Jiang Y; Zhang J
Channels (Austin); 2023 Dec; 17(1):2208928. PubMed ID: 37134043
[TBL] [Abstract][Full Text] [Related]
12. Identification of Gene-Tyrosine Kinase 2 (TYK2) in Head and Neck Squamous Cell Carcinoma Patients-An Integrated Bioinformatics Approach.
Gong X; Ren F
Dis Markers; 2022; 2022():5239033. PubMed ID: 35711568
[TBL] [Abstract][Full Text] [Related]
13. CCR5 as a prognostic biomarker correlated with immune infiltrates in head and neck squamous cell carcinoma by bioinformatic study.
Li C; Chen S; Liu C; Mo C; Gong W; Hu J; He M; Xie L; Hou X; Tang J; Ou M
Hereditas; 2022 Sep; 159(1):37. PubMed ID: 36167571
[TBL] [Abstract][Full Text] [Related]
14. Signal peptidase complex catalytic subunit SEC11A upregulation is a biomarker of poor prognosis in patients with head and neck squamous cell carcinoma.
Hu C; Fan J; He G; Dong C; Zhou S; Zheng Y
PLoS One; 2022; 17(6):e0269166. PubMed ID: 35653344
[TBL] [Abstract][Full Text] [Related]
15. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma.
Shi C; Liu S; Tian X; Wang X; Gao P
BMC Cancer; 2021 Sep; 21(1):1035. PubMed ID: 34530752
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of faciogenital dysplasias as biomarkers in head and neck squamous cell carcinoma.
Ma C; Li H; Li X; Lu S; He J
Biomark Med; 2019 Nov; 13(16):1399-1415. PubMed ID: 31596126
[No Abstract] [Full Text] [Related]
17. Identification of genetic mechanisms underlying lipid metabolism-mediated tumor immunity in head and neck squamous cell carcinoma.
Liu S; Wang S; Wang Z
BMC Med Genomics; 2023 May; 16(1):110. PubMed ID: 37210507
[TBL] [Abstract][Full Text] [Related]
18. NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment.
Chen XM; Liu YY; Tao BY; Xue XM; Zhang XX; Wang LL; Zhong H; Zhang J; Yang SM; Jiang QQ
Front Immunol; 2022; 13():975847. PubMed ID: 36091055
[TBL] [Abstract][Full Text] [Related]
19. Clinical powers of Aminoacyl tRNA Synthetase Complex Interacting Multifunctional Protein 1 (AIMP1) for head-neck squamous cell carcinoma.
Li Y; Liu H
Cancer Biomark; 2022; 34(3):359-374. PubMed ID: 35068446
[TBL] [Abstract][Full Text] [Related]
20. TRIB3, as a robust prognostic biomarker for HNSC, is associated with poor immune infiltration and cancer cell immune evasion.
Wu H; Fu Z; Li H; Fang F; He B; Ye Y; Wu H; Xu D; Zheng H; Zhang Q
Front Immunol; 2023; 14():1290839. PubMed ID: 38235126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
